Osteosarcoma Pathogenesis Leads the Way to New Target Treatments

Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Isabel, Melo-Alvim, Cecília, Lopes-Brás, Raquel, Esperança-Martins, Miguel, Costa, Luís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831017/
https://www.ncbi.nlm.nih.gov/pubmed/33467481
http://dx.doi.org/10.3390/ijms22020813
_version_ 1783641545556099072
author Fernandes, Isabel
Melo-Alvim, Cecília
Lopes-Brás, Raquel
Esperança-Martins, Miguel
Costa, Luís
author_facet Fernandes, Isabel
Melo-Alvim, Cecília
Lopes-Brás, Raquel
Esperança-Martins, Miguel
Costa, Luís
author_sort Fernandes, Isabel
collection PubMed
description Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.
format Online
Article
Text
id pubmed-7831017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78310172021-01-26 Osteosarcoma Pathogenesis Leads the Way to New Target Treatments Fernandes, Isabel Melo-Alvim, Cecília Lopes-Brás, Raquel Esperança-Martins, Miguel Costa, Luís Int J Mol Sci Review Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets. MDPI 2021-01-15 /pmc/articles/PMC7831017/ /pubmed/33467481 http://dx.doi.org/10.3390/ijms22020813 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fernandes, Isabel
Melo-Alvim, Cecília
Lopes-Brás, Raquel
Esperança-Martins, Miguel
Costa, Luís
Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
title Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
title_full Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
title_fullStr Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
title_full_unstemmed Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
title_short Osteosarcoma Pathogenesis Leads the Way to New Target Treatments
title_sort osteosarcoma pathogenesis leads the way to new target treatments
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831017/
https://www.ncbi.nlm.nih.gov/pubmed/33467481
http://dx.doi.org/10.3390/ijms22020813
work_keys_str_mv AT fernandesisabel osteosarcomapathogenesisleadsthewaytonewtargettreatments
AT meloalvimcecilia osteosarcomapathogenesisleadsthewaytonewtargettreatments
AT lopesbrasraquel osteosarcomapathogenesisleadsthewaytonewtargettreatments
AT esperancamartinsmiguel osteosarcomapathogenesisleadsthewaytonewtargettreatments
AT costaluis osteosarcomapathogenesisleadsthewaytonewtargettreatments

Ejemplares similares